Attempts at tumor localization using CU64-labeled copper porphyrins

Bases, Robert; Brodie, Steve; Rubenfeld, Sidney

doi:10.1002/1097-0142(195803/04)11:2<259::aid-cncr2820110206>3.0.co;2-2

Cited by 60 publications

(23 citation statements)

References 10 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This complex is a PET imaging agent targeted against folate receptor positive tumours and has been evaluated as a PET probe for cancer imaging. The 64 Cu-porphyrin is extremely stable and attempts at using it in tumour localisation studies were first reported in the late 1950's; the use of PET radioisotopes in identifying the localisation of brain tumours was reported in the early 1950's 313, 314. Wilson and colleagues attempted to detect brain cancers using 64 Cu-porphyrins and PET imaging in the 1980's but had limited success due to poor tumour localisation properties and poor spatial resolution of the available PET systems 315, 316.…”

Section: Radioimagingmentioning

confidence: 99%

Unique Diagnostic and Therapeutic Roles of Porphyrins and Phthalocyanines in Photodynamic Therapy, Imaging and Theranostics

Josefsen

Boyle²

2012

Theranostics

511

352

View full text Add to dashboard Cite

Porphyrinic molecules have a unique theranostic role in disease therapy; they have been used to image, detect and treat different forms of diseased tissue including age-related macular degeneration and a number of different cancer types. Current focus is on the clinical imaging of tumour tissue; targeted delivery of photosensitisers and the potential of photosensitisers in multimodal biomedical theranostic nanoplatforms. The roles of porphyrinic molecules in imaging and pdt, along with research into improving their selective uptake in diseased tissue and their utility in theranostic applications are highlighted in this Review.

show abstract

Section: Radioimagingmentioning

confidence: 99%

Unique Diagnostic and Therapeutic Roles of Porphyrins and Phthalocyanines in Photodynamic Therapy, Imaging and Theranostics

Josefsen

Boyle²

2012

Theranostics

511

352

View full text Add to dashboard Cite

show abstract

“…Although the positron emission tomography (PET) phenomenon has long been known, it has only recently been recognized as a valuable clinical and theranostic imaging modality in the last decades 110,111. 64 Cu-porphyrins have been explored as promising probes 112,113 considering their favorable properties including excellent resistance to demetallation 109, minimal toxicity 114, the 12 hour half-life of 64 Cu, and the pharmacokinetics of porphyrins 115. Recently, 64 Cu was incorporated into targeted peptide consisting of pyropheophorbide-α, a peptide linker and folate (PPF).…”

Section: The Original Exogenous Agents For Imaging and Therapymentioning

confidence: 99%

Porphyrins as Theranostic Agents from Prehistoric to Modern Times

Zhang¹,

Lovell²

2012

Theranostics

128

View full text Add to dashboard Cite

Long before humans roamed the planet, porphyrins in blood were serving not only as indispensable oxygen carriers, but also as the bright red contrast agent that unmistakably indicates injury sites. They have proven valuable as whole body imaging modalities have emerged, with endogenous hemoglobin porphyrins being used for new approaches such as functional magnetic resonance imaging and photoacoustic imaging. With the capability for both near infrared fluorescence imaging and phototherapy, porphyrins were the first exogenous agents that were employed with intrinsic multimodal theranostic character. Porphyrins have been used as tumor-specific diagnostic fluorescence imaging agents since 1924, as positron emission agents since 1951, and as magnetic resonance (MR) contrast agents since 1987. Exogenous porphyrins remain in clinical use for photodynamic therapy. Because they can chelate a wide range of metals, exogenous porphyrins have demonstrated potential for use in radiotherapy and multimodal imaging modalities. Going forward, intrinsic porphyrin biocompatibility and multimodality will keep new applications of this class of molecules at the forefront of theranostic research.

show abstract

“…Since the total wet mass of the tumour was of the order of 1 g the estimated % total tumour uptake is roughly the same numerically as in this column for comparison with the ROI data. radiolabelled porphyrins and metalloporphyrins for tumour detection in vivo (Figge et al, 1948;Manganiello & Figge, 1951;Bases et al, 1958;Winkelman et al, 1962), but with varying degrees of success. A major problem with the use of these agents has been their high degree of accumulation in the liver, spleen and kidneys (Hambright et al, 1975;Denechaud et al, 1981;Zanelli & Kaelin, 1981).…”

Section: Discussionmentioning

confidence: 99%

Tumour scanning with indium-111 dihaematoporphyrin ether

Quastel

Richter²,

Levy³

1990

Br J Cancer

View full text Add to dashboard Cite

Photofrin II (dihaematoporphyrin ether/ester, DHE) was labelled with indium-111 and its biodistribution in tumour bearing mice compared with that of 111In chloride. The uptake and clearance of 111In labelled DHE differed markedly from that of indium-111 chloride in that the former was not taken up by the tissues as much as the latter. Scintillation scanning with a gamma-camera showed marked uptake of both 111In agents at the site of the tumour, but a much lower tissue background (excluding the abdominal organs) for the mice given 111In DHE. Tumour:muscle ratios of dissected tissues were 2-3 times higher in 111In DHE treated animals as compared to the uptake of 111In chloride. There was a distinct difference in the pattern of distribution of the two 111In preparations in the tissues. The major accumulation of 111In chloride was in the kidneys, whereas the highest uptake of 111In DHE was in the liver, the organ in which unlabelled porphyrins accumulate. Extraction and testing of materials from tumours of 111In DHE treated animals indicated that most of the tumour extractable 111In had remained associated with the porphyrin in vivo up to 4 days after injection. Images Figure 1

show abstract

Attempts at tumor localization using CU64-labeled copper porphyrins

Cited by 60 publications

References 10 publications

Unique Diagnostic and Therapeutic Roles of Porphyrins and Phthalocyanines in Photodynamic Therapy, Imaging and Theranostics

Unique Diagnostic and Therapeutic Roles of Porphyrins and Phthalocyanines in Photodynamic Therapy, Imaging and Theranostics

Porphyrins as Theranostic Agents from Prehistoric to Modern Times

Tumour scanning with indium-111 dihaematoporphyrin ether

Contact Info

Product

Resources

About